health
January 28, 2026
How Orakl Oncology is using DINOv2 to accelerate cancer treatment discovery
Orakl Oncology aims to accelerate cancer research and drug development by combining experimental, lab-based insights and machine learning.
TL;DR
- Orakl Oncology combines experimental insights and machine learning to speed up cancer research and drug development.
- They use lab-grown cancer cells (organoids) to simulate drug performance in patients.
- Meta's DINOv2 model was chosen for its efficiency in interpreting vast imaging data, improving prediction accuracy.
- DINOv2 increased prediction accuracy by 26.8% compared to other techniques.
- The open-source nature of DINOv2 accelerated development and allowed researchers to focus on science.
- Orakl Oncology developed their platform rapidly, achieving in a short time what took others years.
Continue reading the original article